Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Data and trial updates in cardiology, oncology and more.

You may also be interested in...

Task Force’s PSA Proposal Prompts Calls For More Research On Prostate Cancer Diagnostics

Overdiagnosis and overtreatment of prostate cancers that result from screening with prostate-specific antigen tests highlight the need for research on new diagnostics technologies, suggests a new draft statement from the U.S. Preventive Services Task Force.

Boston Sci Makes Its Play In Transcatheter Valves With Sadra Acquisition

Boston Scientific is entering the transcatheter aortic heart valve race in earnest with its deal, announced Nov. 19, to purchase the remainder of start-up firm Sadra Medical for up to $450 million.

Annual CT Screening Offers Big Mortality Benefit To Smokers – NCI

Annual screening of current and former heavy smokers with computed tomography can reduce their risk of dying from lung cancer by about 20%, according to a large National Cancer Institute-backed study.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts